Rahmer Peter's Form 4 filing
Relay Therapeutics, Inc. (RLAY) · filed May 1, 2023
- Accession no.
- 0001209191-23-026280
- Filed
- May 1, 2023
- Trade date
- Apr 28, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $8.25K. It was filed 3 days after the trade.
This filing was later replaced by the amendment 0001209191-23-033421 (Jun 1, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rahmer PeterCIK 0001959229 | Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Common Stock | SSaleDisposed | −739 | $11.16 | −$8,247.24 | 157,504 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Title: Chief Corporate Development Officer